Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study

医学 特应性皮炎 杜皮鲁玛 回顾性队列研究 不利影响 队列 湿疹面积及严重程度指数 内科学 儿科 皮肤病科
作者
Emilio Berná‐Rico,Esther Fiz Benito,José Manuel Busto‐Leis,Guillermo Servera-Negre,Raul de Lucas‐Laguna,Marta Feito Rodríguez
出处
期刊:Dermatology [Karger Publishers]
卷期号:240 (2): 337-342 被引量:18
标识
DOI:10.1159/000535282
摘要

INTRODUCTION: Dupilumab has recently been shown to be effective in children under 6 years of age with atopic dermatitis (AD). Nevertheless, real-life and long-term follow-up data are scarce. We aimed to assess the effectiveness, safety, and long-term outcomes of dupilumab in a daily-practice setting in this age group. METHOD: This was a retrospective observational cohort study. Only patients with 16 or more weeks of treatment were included in the analysis. The proportion of patients who achieved ≥75% or 90% reduction from baseline EASI (EASI75 and EASI90, respectively) and the percentage of patients who achieved vIGA 0-1 were analyzed at 4, 16, 48, 72, and 96 weeks (when available). Adverse events were recorded during follow-up. RESULTS: A total of 19 patients <6 years old with moderate-to-severe AD were included in the cohort, with a median age of 4.7 years (range: 2.6-5.9). The median weeks on dupilumab were 51.3 (IQR: 24.6-79.3). EASI75 was achieved in 11/19 patients (57.9%) at w4, 16/19 (84.2%) at w16, 9/12 (75%) at w48, 6/6 (100%) at w72, and in 2/2 (100%) at week 96. The objective of vIGA 0-1 was reached by 10/19 patients (51.6%) at w4, by 14/19 (73.7%) at w16, by 9/12 (75%) at w48, by 5/6 (83.3%) at w72, and by 2/2 (100%) at w96. Dupilumab was discontinued in 3 patients (15.8%) due to loss of response. One patient developed a paradoxical palmo-plantar eruption. We found no cases of conjunctivitis, facial erythema, or injection-site reactions related to dupilumab. CONCLUSIONS: Dupilumab was effective and safe in our cohort of patients with moderate-to-severe AD under 6 years of age. Response was maintained in the long term in most patients with longer follow-up. Its adverse effect profile was similar to that found in older children and adults.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
复活发布了新的文献求助30
刚刚
细腻驳完成签到,获得积分10
1秒前
1秒前
荼蘼发布了新的文献求助10
1秒前
昏睡的半莲完成签到,获得积分10
2秒前
2秒前
2秒前
Hase发布了新的文献求助10
3秒前
社恐小柠檬完成签到,获得积分10
3秒前
3秒前
aw完成签到,获得积分20
3秒前
4秒前
4秒前
4秒前
pump完成签到,获得积分20
4秒前
风吹麦浪的应助被Eli采纳,获得10
5秒前
5秒前
烟花的应助被4645采纳,获得10
7秒前
张可欣完成签到,获得积分10
8秒前
9秒前
正直未来完成签到,获得积分10
9秒前
张智磊发布了新的文献求助10
10秒前
10秒前
狂野的山菡完成签到,获得积分10
11秒前
荼蘼发布了新的文献求助10
11秒前
12秒前
12秒前
科研通AI2S的应助被开放满天采纳,获得10
14秒前
14秒前
村民完成签到 ,获得积分10
14秒前
molihuakai的应助被活泼的枕头采纳,获得10
16秒前
xucc发布了新的文献求助10
16秒前
喵喵拳发布了新的文献求助10
16秒前
16秒前
super完成签到,获得积分10
16秒前
parad1se完成签到,获得积分10
17秒前
憨子吧完成签到,获得积分10
17秒前
Yy完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241